Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.

Coelho SC, Rocha S, Juzenas P, Sampaio P, Almeida GM, Silva FS, Pereira MC, Coelho MA.

Expert Opin Drug Deliv. 2013 Oct;10(10):1345-52. doi: 10.1517/17425247.2013.827659. Epub 2013 Aug 13.

PMID:
23937147
2.

Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles.

Coelho SC, Rocha S, Pereira MC, Juzenas P, Coelho MA.

J Biomed Nanotechnol. 2014 Apr;10(4):717-23.

PMID:
24734524
3.

Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.

Fahy BN, Schlieman MG, Virudachalam S, Bold RJ.

J Surg Res. 2003 Jul;113(1):88-95.

PMID:
12943815
4.

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3773-81.

5.

Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.

Märten A, Zeiss N, Serba S, Mehrle S, von Lilienfeld-Toal M, Schmidt J.

Mol Cancer Ther. 2008 Nov;7(11):3624-31. doi: 10.1158/1535-7163.MCT-08-0393.

6.

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.

Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach JV, Ciardiello F.

J Cell Physiol. 2008 Sep;216(3):698-707. doi: 10.1002/jcp.21444. Erratum in: J Cell Physiol. 2008 Oct;217(1):290. Tortora, Giampaolo [added].

PMID:
18381602
7.

Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in air-liquid interface conditions.

Lenz AG, Stoeger T, Cei D, Schmidmeir M, Semren N, Burgstaller G, Lentner B, Eickelberg O, Meiners S, Schmid O.

Am J Respir Cell Mol Biol. 2014 Oct;51(4):526-35. doi: 10.1165/rcmb.2013-0479OC.

PMID:
24773184
8.

Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation.

Lee P, Zhang R, Li V, Liu X, Sun RW, Che CM, Wong KK.

Int J Nanomedicine. 2012;7:731-7. doi: 10.2147/IJN.S28783. Epub 2012 Feb 10.

9.

Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.

Frasco MF, Almeida GM, Santos-Silva F, Pereira Mdo C, Coelho MA.

J Biomed Mater Res A. 2015 Apr;103(4):1476-84. doi: 10.1002/jbm.a.35286. Epub 2014 Aug 4.

PMID:
25046528
10.

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.

Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP.

J Cell Biochem. 2001 Apr 2-27;82(1):110-22.

PMID:
11400168
11.

Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.

Lee JK, Ryu JK, Yang KY, Woo SM, Park JK, Yoon WJ, Lee SH, Jeong KS, Kim YT, Yoon YB.

Pancreas. 2011 Aug;40(6):966-73. doi: 10.1097/MPA.0b013e3182156d5a.

PMID:
21487323
12.

Quantitative proteomic analysis to decipher the differential apoptotic response of bortezomib-treated APL cells before and after retinoic acid differentiation reveals involvement of protein toxicity mechanisms.

Uttenweiler-Joseph S, Bouyssié D, Calligaris D, Lutz PG, Monsarrat B, Burlet-Schiltz O.

Proteomics. 2013 Jan;13(1):37-47. doi: 10.1002/pmic.201200233. Epub 2012 Dec 4.

PMID:
23135970
13.

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.

Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI, Hyun MS.

Oncol Rep. 2008 Apr;19(4):1027-32.

PMID:
18357392
14.

Surface functionalized gold nanoparticles for drug delivery.

Cheng J, Gu YJ, Cheng SH, Wong WT.

J Biomed Nanotechnol. 2013 Aug;9(8):1362-9.

PMID:
23926802
15.

[Proteasome inhibitors].

Alexandre J.

Rev Med Interne. 2005 Oct;26(10):812-5. Epub 2005 Aug 11. French.

PMID:
16129520
16.

Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.

Tang ZY, Wu YL, Gao SL, Shen HW.

J Surg Res. 2008 Mar;145(1):111-23. Epub 2007 Aug 22.

PMID:
17714734
17.

Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.

Shen S, Du XJ, Liu J, Sun R, Zhu YH, Wang J.

J Control Release. 2015 Jun 28;208:14-24. doi: 10.1016/j.jconrel.2014.12.043. Epub 2015 Jan 7.

PMID:
25575864
18.

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2010 Jul 21;102(14):1069-82. doi: 10.1093/jnci/djq198. Epub 2010 May 26.

19.

Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, Abbruzzese JL, McConkey DJ.

Cancer Res. 2005 Dec 15;65(24):11658-66. Erratum in: Cancer Res. 2009 Feb 15;69(4):1695.

20.

Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.

Pandit B, Gartel AL.

PLoS One. 2011 Feb 18;6(2):e17110. doi: 10.1371/journal.pone.0017110.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk